Acitretin
- Generic Name
- Acitretin
- Brand Names
- Soriatane
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O3
- CAS Number
- 55079-83-9
- Unique Ingredient Identifier
- LCH760E9T7
- Background
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
- Indication
For the treatment of severe psoriasis in adults.
- Associated Conditions
- Keratinization disorders, Severe Psoriasis
- Associated Therapies
- -
Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01545284
- Locations
- 🇨🇦
Windsor Clinical Research Inc., Windsor, Ontario, Canada
🇨🇦Innovaderm Research Inc., Montreal, Quebec, Canada
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2011-09-29
- Lead Sponsor
- Ministry of Health, China
- Target Recruit Count
- 720
- Registration Number
- NCT01443338
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
- Conditions
- Skin Rash
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT01299220
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Alzheimer's Disease Acitretin Medication
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- K. Lieb
- Target Recruit Count
- 22
- Registration Number
- NCT01078168
- Locations
- 🇩🇪
Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Mainz, Rheinland-Pfalz, Germany
🇩🇪Universität Rostock, Rostock, Germany
Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 61
- Registration Number
- NCT01039142
- Locations
- 🇮🇳
Post Graduate institute Of Medical Education and Research, Chandigarh, India
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
- Conditions
- Moderate to Severe Psoriasis
- Interventions
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00936065
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis
- Conditions
- Psoriasis
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2008-07-28
- Lead Sponsor
- Istituti Fisioterapici Ospitalieri
- Target Recruit Count
- 36
- Registration Number
- NCT00723437
- Locations
- 🇮🇹
Department of Dermatology University of Bologna, Bologna, Italy
Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer
- Conditions
- Non-melanomatous Skin Cancer
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 130
- Registration Number
- NCT00644384
Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 40
- Registration Number
- NCT00395941
- Locations
- 🇮🇳
PGIMER, Chandigarh, India
Acitretin and Etanercept in Psoriasis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-02-16
- Target Recruit Count
- 10
- Registration Number
- NCT00156247
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.